QIAGEN powered by

Enabling Pharmaceutical Development

Whether searching for clinically applicable biomarkers, designing a new companion diagnostic (CDx), or honing your study accrual and go-to-market strategies, we have the pharmaceutical development services to set you on the path to success.

Advance drug development with data from precision medicine testing

The majority of cancer patients today are diagnosed and treated outside the context of clinical research—that is, in the real world.

To improve the efficiency, efficacy, and cost of clinical trials, pharmaceutical companies are using real-world data at each stage of the drug development process.

From biomarker discovery and validation to trial design and label expansion, QIAGEN Real-World Insights (RWI) provides pharmaceutical development services to help you bridge the gap between actionable insight and real-world action.

Live Event

Pistoia Alliance Virtual Conference

On Wednesday, October 21 hear from Dr. Jonathan Sheldon, Senior Vice President of QIAGEN Digital Insights at the Pistoia Alliance Virtual Conference Week. He will be discussing “In Silico Drug Discovery and Development,” and how QIAGEN Real-World Insights is enabling pharmaceutical companies to optimize drug development. 

Cancer drug development takes years. What if there's a faster way?​

Oncology drug development can take up to 15 years, cost millions of dollars, and often relies on sparse data that doesn’t provide a full picture of a target patient population. But what if there’s a faster, safer, and more cost-effective way?

In the June 2020 issue of the Journal of Precision Medicine, Dr. Sheryl Elkin, CSO of QIAGEN Digital Insights, discusses the use of real-world genomic data to overcome the inefficiencies of drug development.

 

Customer Success Story

How Debiopharm uses real-world genomic data to support drug development

Dr. Anna Pokorska-Bocci of Debiopharm International shares her experience working with QIAGEN’s Real-World Insights team and how the customized analyses and offerings provided have enabled Debiopharm to accelerate drug development.

Overcome the inefficiencies of cancer drug development

Drug development is a lengthy, complex, and costly process, entrenched with a high degree of uncertainty that a drug will actually succeed. 

QIAGEN’s Real-World Insights (RWI) portfolio combines robust real-world genomic data from over 200,000 cancer cases and advanced analytics to shorten development timelines, optimize study designs, and improve patient outcomes.

Pharmaceutical development services from QIAGEN

QIAGEN Real-World Insights (RWI) is a professional and personalized pharmaceutical development service dedicated to finding the fastest, most cost-effective route to move therapies from research to market. RWI provides access to real-world genomic data, helping pharmaceutical companies confidently answer critical questions, such as:

  • Which biomarkers to target?
  • What variants to include?
  • Which patients to select?

Pharmaceutical Development Services:

Biomarker and Cancer Indication Selection

Choose the best biomarkers and cancer indications for your molecularly targeted therapies

Cohort Stratification and CDx Design

Identify appropriate patient cohorts and enhance your CDx design to improve stratification and success

Molecular Profiling and Response Analyses

Expand beyond the one biomarker, one drug paradigm with expert molecular profiling and drug-response analyses

Trial Accrual and Drug Market Plans

More easily find the right patients and quickly move to recruitment and regulatory acceptance

Custom Real-World Insights Projects

Create and deliver bespoke RWI projects with a range of flexible options and services tailored to your unique requirements

"Understanding how this kind of real-world data (RWD) can add to the body of evidence to inform regulatory decisions continues to be an area of immense interest in the research and medical community, as well as a key strategic priority for the FDA. At the end of the day, care of an individual patient should be informed by reliable evidence derived from studies reflective of their personal and clinical story."

Amy Abernethy, M.D., Ph.D.,
Principal Deputy Commissioner – Food and Drug Administration (FDA)